Inaugural Ramin Tadayoni Award will be granted at 2024 EURETINA Congress

News
Article

The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research

The European Society of Retina Specialists (EURETINA) announced it has established an award, supported by Oculis Holding AG, in memory of Ramin Tadayoni, MD, PhD. Prof Tadayoni, who passed away suddenly in April, was the EURETINA president and Chief Scientific Officer at Oculis. In a press release, the award was described as “a lasting tribute to Professor Tadayoni’s legacy.”1

A photo of Ramin Tadayoni, MD, PhD. Image courtesy of EURETINA.

Nominations for the Ramin Tadayoni Award are open through 29 July. Image credit: EURETINA.

“The Ramin Tadayoni Award has been established to honour the memory of a remarkable individual whose contributions significantly advanced ophthalmic disease research,” said Anat Loewenstein, MD, President of EURETINA. She described Prof Tadayoni as a visionary leader and a cherished friend. “This initiative serves both as a legacy to an incredible man and a tribute to his work. By preserving the contributions of Prof. Tadayoni, we are also investing in the future generation of brilliant ophthalmologists who will drive research excellence and innovation in retinal care.”

The Ramin Tadayoni award will be presented to talented ophthalmologists who have made outstanding contributions and have exceptional potential in retina research. The annual award will grant €30,000 for research support, and an additional €5,000 directly to the candidate. Applications are open now, and will be accepted through July; the inaugural award will be presented at the 2024 EURETINA Congress, 19 - 22 September.

Prof Tadayoni was a professor of ophthalmology at the University of Paris. He was also head of the ophthalmology department at the Fondation Adolphe de Rothschild Hospital, where he served as director of the French Myopia Institute, and the Lariboisière and Saint-Louis University Hospital, both in Paris.

At the time of his passing, Prof Tadayoni was only a few months into his 2-year term as EURETINA president. In an interview about his plans for the future of the organisation, Tadayoni said he planned to advocate for changes to funding throughout Europe to increase the scope of research in the field.2 “We have a lot of challenges as retinal specialists in terms of keeping pace with a rapidly evolving landscape in terms of new treatments, regulations, technologies and innovations coming on stream,” Prof Tadayoni said at the time. As such, the award’s research funding will help to carry out Prof Tadayoni’s stated goals for EURETINA and the retina research community worldwide.

Prof Tadayoni was appointed Chief Scientific Officer of Oculis in February 2024, and had previously served as Chair of the Oculis Retina Scientific Advisory Board. Riad Sherif, MD, Chief Executive Officer of Oculis, said that Prof Tadayoni was an “exceptional friend” who “played a key part in Oculis progress since its inception.” In the news release announcing the award,1 Dr Sherif stated, “In addition to his scientific achievements, he is remembered for his kindness, mentorship and unwavering commitment to advancing the field and bettering patients’ lives. Prof Tadayoni has left behind a profound legacy and we are very pleased that this award will carry forward his dedication to high quality research in the field of retina, to education, and to patients suffering from blinding diseases.”

On its website, EURETINA shared3 eligibility criteria for the award. These include:

  • Applicants must be post-doctoral or clinical fellows conducting research in the retina field in a specialised retinal unit or university hospital in a European country. (For the purposes of the award, a European country includes all member states of the European Union (EU), countries within the European Economic Area (EEA), Switzerland and the United Kingdom.)
  • Applicants must hold an M.D. and/or Ph.D. and have completed their most recent doctoral degree or medical residency within the past ten years by the start of this award in 2025.
  • Applicants must be current EURETINA members.

Applications are currently open online close on Monday 29th July 2024. The winning applicant will be chosen by a panel of leading retina specialists nominated by the EURETINA Board and Oculis. To apply, please visit the EURETINA website: https://euretina.org/ramin-tadayoni-award-terms/

References

1. Oculis Holding AG. Oculis and EURETINA Announces the Ramin Tadayoni Award. News release. Published 27 June, 2024. Accessed 27 June, 2024. https://www.globenewswire.com/news-release/2024/06/27/2905032/0/en/Oculis-and-EURETINA-Announces-the-Ramin-Tadayoni-Award.html
2. Hayes, H. Retina community mourns sudden loss of Ramin Tadayoni, MD, PhD. Ophthalmology Times Europe. Published 22 April, 2024. Accessed 27 June, 2024. https://europe.ophthalmologytimes.com/view/retina-community-mourns-sudden-loss-of-ramin-tadayoni-md-phd-euretina-death-obituary
3. The Ramin Tadayoni Award. EURETINA.org.
Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.